My Treatment Approach: Recent Advances in the Treatment of Multiple Myeloma in Early Relapse

home / insights / my-treatment-approach-recent-advances-in-the-treatment-of-multiple-myeloma-in-early-relapse

Brea Lipe, MD, and Peter Forsberg, MD, discuss updates in the treatment of R/R multiple myeloma, and present two hypothetical patient profiles to show how recent data can be incorporated into clinical practice.

Patient Profile 1: A 63-Year-Old Female with Relapsed Multiple Myeloma

EP. 1: Patient Profile 1: A 63-Year-Old Female with Relapsed Multiple Myeloma

Brea Lipe, MD;Peter Forsberg, MD
August 18th 2022

Brea Lipe, MD, and Peter Forsberg, MD, present the profile of a woman with multiple myeloma in early relapse and discuss their treatment strategy.

Treatment Options for Patients with Multiple Myeloma in Early Relapse

EP. 2: Treatment Options for Patients with Multiple Myeloma in Early Relapse

Brea Lipe, MD;Peter Forsberg, MD
August 18th 2022

An overview of the available treatment options in relapsed/refractory multiple myeloma.

IKEMA Trial of Isatuximab plus Carfilzomib and Dexamethasone in R/R MM

EP. 3: IKEMA Trial of Isatuximab plus Carfilzomib and Dexamethasone in R/R MM

Brea Lipe, MD;Peter Forsberg, MD
August 25th 2022

Dr Peter Forsberg reviews clinical trial data on a triplet treatment regimen for relapsed/refractory multiple myeloma.

Clinical Implications of the IKEMA Trial in R/R MM

EP. 4: Clinical Implications of the IKEMA Trial in R/R MM

Brea Lipe, MD;Peter Forsberg, MD
August 25th 2022

Dr Forsberg details the safety data and toxicity management strategies of the IKEMA clinical trial.

Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

EP. 5: Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

Brea Lipe, MD;Peter Forsberg, MD
September 1st 2022

Oncologists debate which patient populations most benefit from isatuximab plus carfilzomib and dexamethasone.

Treatment of Patients With MM and High-Risk Cytogenetics

EP. 6: Treatment of Patients With MM and High-Risk Cytogenetics

Brea Lipe, MD;Peter Forsberg, MD
September 1st 2022

Dr Brea Lipe explains at what stages she orders genetic testing in patients with relapsed/refractory multiple myeloma and how she approaches the treatment of patients with high-risk cytogenetics.

Patient Profile 2: A 76-Year-Old Female with R/R MM

EP. 7: Patient Profile 2: A 76-Year-Old Female with R/R MM

Brea Lipe, MD;Peter Forsberg, MD
September 8th 2022

Brea Lipe, MD, and Peter Forsberg, MD, present the profile of a woman with relapsed/refractory multiple myeloma and share their opinions of the treatment regimen.

CANDOR Trial of Daratumumab Plus Carfilzomib and Dexamethasone in R/R MM

EP. 8: CANDOR Trial of Daratumumab Plus Carfilzomib and Dexamethasone in R/R MM

Brea Lipe, MD;Peter Forsberg, MD
September 8th 2022

Brea Lipe, MD, and Peter Forsberg, MD, review the results of the CANDOR trial evaluating DARA-Kd regimen in R/R multiple myeloma.

Selecting Patients for Treatment With DARA-Kd

EP. 9: Selecting Patients for Treatment With DARA-Kd

Brea Lipe, MD;Peter Forsberg, MD
September 15th 2022

Peter Forsberg, MD, offers insight into which patients with multiple myeloma are most suitable for treatment with the DARA-Kd regimen.

Sequencing Therapies in Patients With R/R MM

EP. 10: Sequencing Therapies in Patients With R/R MM

Brea Lipe, MD;Peter Forsberg, MD
September 15th 2022

Drs Forsberg and Lipe discuss strategies for sequencing therapies in relapsed/refractory multiple myeloma.

Advice for Community Oncologists Treating Patients With R/R MM

EP. 11: Advice for Community Oncologists Treating Patients With R/R MM

Brea Lipe, MD;Peter Forsberg, MD
September 15th 2022

Drs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.